Abstract
During the very early phase of stroke recovery, the brain is hypothesized to be in a neuroplastic state that is responsive to external stimuli. Here, brain-derived neurotrophic factor (BDNF) is thought to play an important role. BDNF, a member of the neurotrophin family, is implicated in processes such as synaptogenesis and long-term potentiation. Post-stroke, reduced BDNF levels are observed compared to the healthy population. An intervention that has been shown to elevate BDNF is Aerobic exercise. Yet, the impact of aerobic exercise in stroke patients remains unclear. This sub-analysis of the multicenter, randomized, controlled ’Physical Fitness Training in Patients with Subacute Stroke’ trial aimed to investigate serum BDNF dynamics and the effects of a four-week aerobic exercise intervention on long- term BDNF levels.
Data from 200 patients, with missing data imputed, revealed a modest increase in serum BDNF levels up to three months post-stroke (22.6 ng/ml, 95% CI 19.2 to 26) which plateaued until six months (24.3 ng/ml, 95% CI 20.6 to 27.9). Despite higher baseline BDNF levels in the exercise group, no treatment effect was observed until six months (training 24.6 ng/ml, 95% CI 20.2 to 29 vs relaxation: 24.3 ng/ml, 95% CI 19.8 to 28.8, p = 0.95). A sex-related interaction was identified in the relaxation group, with female patients exhibiting higher BDNF increases until end of follow up (20.9 ng/ml, 95% CI 15.7 to 26.2 (males) vs 31.0 ng/ml, 95% CI 22.9 to 39.0 (females), p = 0.039). Dose-response analyses and associations with recurrent events yielded no substantial differences.
While serum BDNF levels increased early after stroke in the first three months, aerobic exercise did not demonstrate a significant impact on BDNF levels within this dataset. Further investigations with more measurements during the early subacute phase are warranted to elucidate the interplay between exercise, BDNF, and recovery.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
clinicaltrials.gov identifier NCT01953549
Clinical Protocols
https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-15-45
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was approved by the local ethics committee of the Charité University Medicine Berlin (EA1/138/13) and patients gave written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Related data to the primary efficacy endpoints have been published previously. Analysis scripts unique to the current manuscript are freely accessible on github: https://github.com/Funkstille1011/BDNF
